3-(4-propyl-1-piperazinyl)-1-propanol | 100500-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(4-propyl-1-piperazinyl)-1-propanol
• 英文别名: 3-(4-Propylpiperazin-1-yl)propan-1-ol
• CAS: 100500-96-7
• 化学式: C₁₀H₂₂N₂O
• 分子量: 186.297
• InChiKey: VUJXOWLBYRNRLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(4-丙酰基-1-哌嗪基)丙酸丙酯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以64%的产率得到3-(4-propyl-1-piperazinyl)-1-propanol
  参考文献：
  名称：

  Kafka, Stanislav; Cermak, Jan; Novak, Tomas, Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 5, p. 1201 - 1211

  摘要：

  DOI：

文献信息

• OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME
  申请人：SHIOZAKI Hiroyoshi

  公开号：US20090306376A1

  公开（公告）日：2009-12-10

  A compound comprising a ring structure including a ring composed of four carbon atoms and two nitrogen atoms and a substituted or unsubstituted amino group bonded to the ring structure.

  一种化合物，包括一个环结构，其中包括由四个碳原子和两个氮原子组成的环，以及与环结构相结合的取代或未取代的氨基团。
• Hetereoaryl nitrile derivatives
  申请人：Altmann Eva

  公开号：US20060142575A1

  公开（公告）日：2006-06-29

  The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供了式（I）的化合物或其药学上可接受的盐或酯，其中符号的含义如定义所述，这些化合物是猫hepsin K的抑制剂，并且在药学上用于治疗与猫hepsin K有关的疾病和医疗状况，例如各种疾病，包括炎症，类风湿性关节炎，骨关节炎，骨质疏松症和肿瘤。
• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：OHTAKE Yasuhiro

  公开号：US20080076760A1

  公开（公告）日：2008-03-27

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明旨在提供一种以公式（1）表示的2,3,4,5-四氢-1H-1,5-苯并二氮平衍生物或其药学上可接受的盐，该化合物可作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药物。
• HETEROARYL NITRILE DERIVATIVES
  申请人：Altmann Eva

  公开号：US20090227596A1

  公开（公告）日：2009-09-10

  The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供公式I的化合物或其药学上可接受的盐或酯，其中符号的含义如定义所述，这些化合物是卡他普星K的抑制剂，并且在药学上用于治疗与卡他普星K有关的疾病和医疗状况，例如各种疾病，包括炎症，类风湿性关节炎，骨关节炎，骨质疏松和肿瘤。
• OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM
  申请人：Mitsui Chemicals, Inc.

  公开号：EP1672626A1

  公开（公告）日：2006-06-21

  There are provided an optical recording medium which enables recording and playback with high quality using laser of 300 nm to 900 nm and a novel compound. An optical recording medium wherein the percentage change (|[a2 - a1]/a1| × 100) of the recording layer thickness (a2) at the recorded site of recording layer (A) after recorded with laser light compared with the recording layer thickness (a1) at unrecorded site of said recording layer (A) is less than 25% and the amount of change (|a2 - a1|) of the recording layer thickness (a2) at recorded site of said recording layer (A) after recorded with laser light compared with the recording layer thickness (a1) at unrecorded site of said recording layer (A) is controlled to be less than 15 nm. A compound comprising a six-membered ring structure composed of four carbon atoms and two nitrogen atoms and a substituted or unsubstituted amino group bonded.

  本发明提供了一种光学记录介质，利用波长为 300 纳米至 900 纳米的激光和一种新型化合物可实现高质量的记录和重放。 一种光学记录介质，其中用激光记录后，记录层（A）的记录部位的记录层厚度（a2）与未记录部位的记录层厚度（a1）相比的变化百分比（|[a2-a1]/a1| ×100）小于 25%，且所述记录层（A）的记录部位的记录层厚度（a2）与未记录部位的记录层厚度（a1）相比的变化量（|a2-a1|）小于 25%。a1|）的变化量控制在 15 nm 以下。 一种由四个碳原子和两个氮原子以及一个取代或未取代的氨基键合而成的六元环结构的化合物。